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ABSTRACT  
 
Recent data suggest that deletion of p16INK4 and mutation of TP53 are among the most 
common genetic events in the development of human cancer, since the codified proteins 
act as brakes of the abnormal cell cycle. As the molecular events leading to the 
development of pediatric bone sarcomas remain unclear, we analyzed 75 osteosarcoma 
and Ewing sarcoma samples from 43 pediatric patients to search for alterations at the 
TP53 or p16INK4 tumor suppressor genes. By means of PCRDGGE (polymerase chain 
reaction and denaturing gradient gel electrophoresis) we detected TP53 point mutations 
in 18.6% of the tumor samples, but no constitutional mutations. In the analysis of 
p16INK4, 7% of the samples harbored deletions of the gene but no point mutations 
were detected by SSCP (single strand conformation polymorphism) analysis, just the 
polymorphism Ala —› Thr at codon 148. These data support the hypothesis that TP53 
alterations may play a role in the development of pediatric bone tumors and that the 
primary mechanism of inactivation of p16INK4 seems to be homozygous deletion 
rather than point mutation.  
  
 
 
INTRODUCTION 
 
The molecular events leading to the development of pediatric bone tumors remain 
unclear and, to date, the oncogenes or tumor suppressor genes responsible have not been 
reported. Nevertheless, genetic alterations which affect normal function of RB-1 and 
TP53 tumor suppressor genes have been demonstrated in these types of tumors [13], 
although other genetic events critical for tumorigenesis have not yet been well defined. 
 
Recently, it has been reported that deletion of the p16INK4 gene is common in various 
human tumors [4], and the encoded protein has been identified as a regulatory product 
in the cell cycle. p16INK4 inhibits the CDK4-cyclin D complexes, preventing the 
phosphorylation of regulatory proteins which block G1 to S transition and cell growth 
[5]. 
Homozygous deletions and mutations at the p16INK4 locus (9p21) have been 
demonstrated in a wide variety of tumor-derived cell lines, although the overall 
incidence of alterations is less in primary tumors than in cell lines [6]. This fact may 
represent an "in vitro" artifact or suggest the presence of another nearby tumor 
suppressor gene. In a previous study, point mutations affecting p16INK4 were detected 
in several sarcoma cell lines, but not in cell fines derived from osteosarcoma, in which 
only homozygous deletions were reported, suggesting that alterations may originate by 
different mechanisms, depending on the tissue type [7]. In addition, little data 
concerning primary pediatric bone tumors has been published so far, and it is unclear to 
what extent alterations in the p16INK4 gene are relevant to their development. 
 
Mutations affecting the TP53 tumor suppressor gene at 17p are the most common 
genetic alterations yet identified in sporadic human tumors [8]. This gene acts as a 
transcriptional activator and plays a key role in suppressing abnormal cell proliferation 
by acting as a G1 cell cycle checkpoint for DNA damage [9-10]. 
 
In the present study, we examined alterations of p16INK4 and TP53 genes in 
osteosarcomas and Ewing sarcomas in which absence of point mutations at codons 12 
and 61 of the RAS-family genes had already been demonstrated [11], in order to 
determine if, and to which extent, these genes are involved in carcinogenesis in this 
subset of pediatric bone tumors. 
 
 
 
MATERIALS AND METHODS 
 
Patients and Samples 
 
Primary tumors and peripheral blood samples were obtained from patients treated at the 
Clínica Universitaria in Pamplona, Spain. 75 samples from 43 patients were examined: 
38 osteosarcomas and five Ewing sarcomas. Matched normal DNA was available for 11 
of these patients. In addition, we analyzed 20 peripheral blood samples from bone 
sarcoma patients for whom tissue samples were not available in order to test the 
possibility that they harbor constitutional alterations. 
 
Genomic DNA was obtained by isolation and purification with proteinase K and 
extraction using conventional phenol-chloroform procedures in the case of peripheral 
lymphocytes (n = 31) and fresh tissues (n = 15). Serial cuts were obtained from 
paraffin-embedded samples (n = 49) and they were deparaffinized following 
conventional procedures with slight modifications [12]. 
 
 
P16INK4 Analysis 
 
PCR and SSCP. Exons 1 and 2 of the p16INK4 gene were amplified using primers and 
under conditions described elsewhere [13]. In brief, 200 ng of genomic DNA was 
amplified in a 25 µl PCR reaction containing 10 pmol of each primer, 200 µM dNTPs, 
20 mM Tris-HC1 (pH 8.5), 16 mM SO4(NH4)2, 2.5 mM MgCl2, 150 µg/ml BSA, 5% 
DMSO, and 1 unit of Taq DNA polymerase (BioTaqTM, Bio-probe Systems). 
SSCP analysis was performed on a 12% polyacrylamide gel (49:1 acrylamide: 
bisacrylamide) containing 10% glycerol. Before electrophoresis, 2 µl sample was added 
to 10 µl stop solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, and 
0.05% xylene cyanol), heated to 95°C for 6 minutes and immediately placed on ice. 
Electrophoresis in a 4°C chamber was maintained at 200 volts until the xylene cyanol 
reached the bottom of the gel. After electrophoresis, bands were visualized by silver 
staining as described by Hiort [14]. 
 
When necessary, SSCP analysis was repeated after digestion of the PCR fragments with 
the restriction enzyme SmaI. 
 
Recognition of the A148T polymorphism at exon 2 of the p16INK4 gene was by failure 
to digest with SacII. 
 
 
P16INK4 Deletion Analysis 
 
To investigate the presence of homozygous deletion for the p16INK4 gene, we 
coamplified p16INK4 exon 2 with a 220 bp fragment of the Vδ2 region of the TCR (T-
cell receptor) gene as control for amplification. The PCR reaction was similar to those 
conditions described above. 
 
For visualization, PCR fragments were separated by electrophoresis on a 2% agarose 
gel containing 0.5 µg/µl ethidium bromide and photographed under UV light. To enable 
comparison of both PCR products, the PCR reaction was maintained within the 
exponential range of amplification, minimizing the amount of starting DNA and the 
cycle number. 
 
Homozygous deletion results were interpreted if there was complete absence of the 
amplification signal of the p16INK4 exon 2 fragment in three separate reactions. 
 
 
TP53 Mutation Analysis and DNA Sequencing 
 
Screening for mutations at the TP53 gene was performed as previously described [15, 
16] with slight differences in running times. 
 
Bands with altered electrophoretic mobilities were sequenced by cycle sequencing using 
the Thermo SequenaseTMCycle Sequencing kit (Amersham Life Science). 
 
  
 
RESULTS 
 
Screening for TP53 Mutations 
 
We analyzed exons 5 through 8 of the TP53 tumor suppressor gene because this region 
accounts for about 80% of the conserved domains of the gene, and is the location of 
more than 95% of the mutations reported in sporadic tumors. 
We detected alterations in 10 samples corresponding to eight patients: seven 
osteosarcomas and one Ewing sarcoma (Figs. 1 and 2). The locations of the mutations 
were as follows: four in exon 8, two in exon 5, and one in exons 6 and 7 respectively 
(Table 1). We detected alterations in 18.6% of the patients, which confirms previous 
reports indicating an important role for the TP53 gene in carcinogenesis. It is 
noteworthy that alterations were found to be present in primary (43B, 45A, 46B, 22C), 
recurrent (45B), and metastasic (2C, 15C, 19R, 45C, 80R) samples. 
 
 
Screening for p16INK4 Deletions 
 
Homozygous deletions of p16INK4 were detected in five samples belonging to three 
patients (Fig. 3). This suggests an overall frequency for homozygous deletion of 7%, 
not substantially different from that reported for adult primary tumors [17]. Al) three 
patients had osteosarcomas at stage IIB, according to the Enneking classification [18]. 
  
In the case of one of the osteosarcoma patients, samples from the primary tumor and 
from two different metastases were available, and we detected homozygous deletions in 
all of them. 
 
 
Screening for p16INK4 Point Mutations 
 
The SSCP analysis of exons 1 and 2 of the gene identified four samples with identical 
altered SSCP pattern for exon 2 compared to controls carrying known mutations. 
Digestion with SacII revealed the polymorphism A148T that was present in our series 
with a frequency of 3.2% (Fig. 4). 
 
We found no mutations affecting the coding region of exons 1 or 2 of the p16INK4 
gene in our tumors or blood samples. 
 
 
 
DISCUSSION 
 
Clinical follow-up data from diagnosis to present was available for all bone sarcoma 
patients in this study, and covers development of metastases, treatment, disease-free 
survival time, and total survival time. 
 
Our study of 43 pediatric patients with bone sarcomas revealed alterations of the 
p16INK4 tumor suppressor gene in 7% of the samples, and point mutations of TP53 in 
18.6%. These values are both in agreement with those previously reported, and support 
the hypothesis that the main mechanism of inactivation of the p16INK4 gene in primary 
tumors is homozygous deletion. They also support the idea that TP53 alterations may 
play a role in the development of pediatric, as well as adult, osteosarcoma. 
 
Missense mutations in the evolutionarily conserved codons of the TP53 gene (codons 
118 to 280) are commonly implicated in the development of human cancer. In our 
series, 75% of mutant samples were found to carry such mutations. 
All TP53 mutations we found have already been reported in the literature [19]; some of 
them—such as the Arg to His change at codon 273 and the generation of the stop codon 
at position 196—have been described in a wide variety of tumors and cell lines, while 
the missense mutation at codon 268 and the frameshift and tandem mutation at exon 7 
have only been reported, to our knowledge, in two cases each, and never occurring in 
the same patient. 
 
It was not possible to obtain DNA of sufficient quality for sequencing from one tumor 
sample (2C, Table 1), and therefore we do not know the nature and position of this 
alteration affecting the exon 5 of the gene. The possibility that the nucleotide alteration 
present in the tumor does not change the encoded aminoacid or changes it unto a 
synonymous one cannot be excluded; this would therefore represent a genetic 
polymorphism with no clinical implication. The PCR amplification fragment 
corresponding to the sample migrated more slowly in the DGGE gel than the control 
fragment, and it would therefore be predicted to have suffered a GC to AT change. 
 
It may well be that another gene or genes involved in the TP53 regulatory pathway are 
altered in these tumors. 
  
A good candidate is the MDM2 (murine double minute-2) gene which encodes a protein 
that may interact with p53 protein, inhibiting TP53 mediated transactivation. These two 
proteins, MDM2 and p53, are parts of an autoregulatory loop in which the MDM2 
mRNA transcription is enhanced by p53 overexpression. In previous reports [20, 21] it 
has been demonstrated that between 15% and 30% of human osteosarcomas and soft 
tissue sarcomas present MDM2 amplification and that none of the tumors with MDM2 
amplification had mutated TP53; therefore, amplification of MDM2 may provide an 
alternative mechanism for TP53 inactivation. 
 
In our deletion analysis of p16INK4, we considered homozygous deletions in those 
patient samples in which complete absence of the amplification fragment of the exon 2 
of the gene was demonstrated. Nevertheless, our frequency of homozygous deletions 
may be an underestimate of the real number because some hemizygously and even 
homozygously deleted samples may appear as non-deleted due to the amplification of 
the one allele present or even to amplification of normal p16INK4 alleles present in 
spurious normal cells in the tumor samples. 
 
The absence of mutations in the p16INK4 gene in our series is not a surprising fact, 
given the low frequency of such alterations detected in adult osteosarcoma patients [17]. 
Alternatively, it may be that the SSCP technique which we used for the screening failed 
to detect the alterations, given that the amplification size (350 bp for exon 1 and 347 bp 
for exon 2) is at the upper limit of what the technique can discriminate [22]. In view of 
this possibility, we also digested the amplification products of exons 1 and 2 with the 
restriction enzyme SmaI, thus obtaining ideal fragments for analysis by SSCP. 
 
We also tried to analyze fragments by DGGE, which can detect 100% of the alterations 
in a given DNA fragment [23]. Despite achieving very good melting profiles for exons 
1 and 2 of the p16INK4 gene, the high GC content of the fragments raised the melting 
temperature over the limits of resolution for conventional DGGE gels. 
 
In the SSCP analysis of exon 2 of the p16INK4 gene, we found four samples from two 
patients that showed identical SSCP banding patterns clearly different from those of the 
normal controls. The fact that two of the four samples were DNAs extracted from 
peripheral blood led to the suspicion that these alterations may be accounted for by a 
polymorphism. Failure to digest with SacII and the size of the resulting fragments 
indicated the presence of the polymorphism A148T; this base change (G → A) 
abolishes the SacII restriction site and changes codon 148 from alanine to threonine. 
The frequency of this polimorphism in our series was 3.2%, lower than that reported by 
Sun et al. [13] for white Caucasians. The difference is significant and may reflect 
differences in populations, as has been demonstrated with Alaskan individuals. 
 
In our series, we found that the three patients with a deleted p16INK4 gene were 
diagnosed as having chondroblastic osteosarcoma, and all developed lung metastases 
and died within a period of between 16 and 34 months. This suggests that deletion of 
p16INK4 may be valuable as a prognostic factor associated with tumors of more 
aggressive behavior, although this series is too small to draw definitive clinical 
conclusions. 
 
It has been demonstrated that there seems to exist an inverse correlation between the 
present of the p16INK4 encoded protein and that of the RB1 gene (p110RB). The ex-
planation for this fact is that the suppressive potential of p110RB is inactivated by 
phosphorylation, which can be inhibited by p16INK4 binding to the corresponding 
CDK [24]. Therefore, loss or alteration of p16INK4 expression would affect the 
functions of p110RB. Thus, it seems that loss of p16INK4 and loss of RB may have 
similar effects on cell cycle progression and that they are part of the same pathway in 
tumorigenesis; this has a special meaning in bone sarcomas, in which RB1 mutations 
have been demonstrated to happen non-randomly [2, 3]. 
 
Lung metastasis developed in half of the patients whose primary tumors harbored 
mutations at the TP53 gene, but four osteosarcoma patients showed no evidence of 
disease during the time following their initial treatment, although TP53 mutations were 
identified in their samples. Therefore, no definite association was observed between 
TP53 mutation and the incidence of metastases. We did not find association with any 
other clinical parameters, such as tumor grading or histologic subtypes, either; although 
in previous reports [25-27] it has been suggested that the presence of an altered TP53 
gene may be related to more aggressive or invasive tumors. 
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 Table 1. TP53 mutations found in the DGGE analysis of the tumor samples 
Sample 
N° Exon Codon DNA change Protein change Tumor 
22C 8 273 CGT → CAT Arg → His Osteosarcoma (0)1
80R 8 273 CGT → CAT Arg → His Ewing Sarcoma 
45A,B,C 8 273 CGT → CAT Arg → His Osteosarcoma (C)2
43B 8 268 AAC → AGC Asn → Ser Osteosarcoma (O) 
19R 7 250 delC Frameshift Osteosarcoma (C) 
  250-251 CCC → TTC Pro → Phe (same) 
46B 6 196 CGA → TGA Arg → Stop Osteosarcoma (F)3
15C 5 175 CGC → CAC Arg → His Osteosarcoma (O) 
2C 5 ? ? ? Osteosarcoma (O) 
1Osteoblastic subtype. 
2Chondroblastic subtype. 
3Fibroblastic subtype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Direct genomic sequence analysis of the PCR amplification of the TP53 exon 
7 of patient 19R showing deletion of a C in allele 1 and the CCC to TTC tandem change 
in the non-deleted allele (allele 2). 
 
 
 
 
 
Figure 2. Partial sequence of TP53 exon 6 of patient 46B versus a normal control, 
showing a CGA to TGA change that changes the wild type arginine codon into a stop 
codon. 
 
 
 
 
 
 
 
 
Figure 3. Coamplification of the p16INK4 exon 2 and the TCR fragment showing 
absence of amplification of the fragment corresponding to p16INK4 in lanes 2, 3, and 4. 
M = molecular weight marker, and lanes 1, 5, 6, and 7 are non-deleted samples. 
 
 
 
 
 
  
 
Figure 4. SacII digestion of the amplification of p16INK4 exon 2, showing a non-
digested allele in one tumor sample carrying the polymorphism A148T (lane with an 
arrow). 
 
 
 
 
 
 
